1. Home
  2. NVAX vs VERA Comparison

NVAX vs VERA Comparison

Compare NVAX & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVAX
  • VERA
  • Stock Information
  • Founded
  • NVAX 1987
  • VERA 2016
  • Country
  • NVAX United States
  • VERA United States
  • Employees
  • NVAX N/A
  • VERA N/A
  • Industry
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • VERA Biotechnology: Pharmaceutical Preparations
  • Sector
  • NVAX Health Care
  • VERA Health Care
  • Exchange
  • NVAX Nasdaq
  • VERA Nasdaq
  • Market Cap
  • NVAX 1.3B
  • VERA 2.0B
  • IPO Year
  • NVAX 1995
  • VERA 2021
  • Fundamental
  • Price
  • NVAX $6.80
  • VERA $24.00
  • Analyst Decision
  • NVAX Buy
  • VERA Buy
  • Analyst Count
  • NVAX 5
  • VERA 8
  • Target Price
  • NVAX $16.60
  • VERA $64.63
  • AVG Volume (30 Days)
  • NVAX 5.2M
  • VERA 2.3M
  • Earning Date
  • NVAX 08-07-2025
  • VERA 08-07-2025
  • Dividend Yield
  • NVAX N/A
  • VERA N/A
  • EPS Growth
  • NVAX N/A
  • VERA N/A
  • EPS
  • NVAX 2.97
  • VERA N/A
  • Revenue
  • NVAX $1,254,962,000.00
  • VERA N/A
  • Revenue This Year
  • NVAX $56.85
  • VERA N/A
  • Revenue Next Year
  • NVAX N/A
  • VERA N/A
  • P/E Ratio
  • NVAX $2.29
  • VERA N/A
  • Revenue Growth
  • NVAX 25.92
  • VERA N/A
  • 52 Week Low
  • NVAX $5.01
  • VERA $18.53
  • 52 Week High
  • NVAX $17.81
  • VERA $51.61
  • Technical
  • Relative Strength Index (RSI)
  • NVAX 51.68
  • VERA 54.33
  • Support Level
  • NVAX $6.23
  • VERA $22.76
  • Resistance Level
  • NVAX $6.90
  • VERA $23.97
  • Average True Range (ATR)
  • NVAX 0.30
  • VERA 1.21
  • MACD
  • NVAX 0.01
  • VERA 0.15
  • Stochastic Oscillator
  • NVAX 67.00
  • VERA 73.63

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Share on Social Networks: